Colorectal cancer is the third most common cancer in both men and women in the United States. There is growing evidence that pathogenic alterations in the composition of the gut microbiome, also known as dysbiosis, can disrupt intestinal homeostasis, promote inflammation, and increase susceptibility to cancer. In contrast, in the absence of dysbiosis, the gut microbiota largely benefit the host, such as by promoting the development of the gut immune system, facilitating dietary metabolism, and preventing pathogen colonization. However, the function of specific members of the gut microbiota and the mechanism by which the gut microbiota modulates tumor susceptibility have not been clearly defined. Based on our preliminary data, our central hypothesis is that a limited number of bacterial species is capable of reducing colon cancer risk. The purpose of our proposed studies is to further our understanding of the mechanism by which commensal bacteria modulate colon cancer risk using mice models complemented by metabolomics and proteomics. Our long-term goal is to develop a probiotic cocktail of human commensal bacteria that can be used to reduce risk of developing colon cancer, particularly in high risk populations, such as patients with inflammatory bowel disease, familial adenomatous polyposis, or recurrent adenomas.

Public Health Relevance

Colorectal cancer is the third most common cancer in the United States and second leading cause of cancer-related mortality in both men and women combined. Non-steroidal anti- inflammatory drugs, including Cox-2 inhibitors, have shown promise in reducing disease risk; however, these drugs are often associated with significant toxicities, and therefore, there is a clear need to develop other novel chemoprevention strategies. The proposed studies will help provide a better understanding of how certain bacterial strains can be helpful in limiting tumorigenesis using mice models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA191744-01
Application #
8814012
Study Section
Special Emphasis Panel (ZCA1-SRB-2 (O1))
Program Officer
Flores, Roberto L
Project Start
2014-12-08
Project End
2016-11-30
Budget Start
2014-12-08
Budget End
2015-11-30
Support Year
1
Fiscal Year
2015
Total Cost
$202,655
Indirect Cost
$72,155
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Chen, Grace Y (2017) Regulation of the gut microbiome by inflammasomes. Free Radic Biol Med 105:35-40
Seregin, Sergey S; Golovchenko, Natasha; Schaf, Bryan et al. (2017) NLRP6 Protects Il10-/- Mice from Colitis by Limiting Colonization of Akkermansia muciniphila. Cell Rep 19:733-745
Wu, Jing; Zhu, Jianhui; Yin, Haidi et al. (2016) Development of an Integrated Pipeline for Profiling Microbial Proteins from Mouse Fecal Samples by LC-MS/MS. J Proteome Res 15:3635-3642